Chemical Name: | (E)-4-[(2R,4R,5S,6R)-2-hydroxy-2-[(2S,3R,4S)-3-hydroxy-4-[(2R,3S,4E,6E,9S,10S,11R,12E,14E)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-5-methyl-6-propan-2-yloxan-4-yl]oxy-4-oxobut-2-enoic acid |
CAS Number: | 88979-61-7 |
Product Number: | AG00454M(AGN-PC-00FRD7) |
Synonyms: | |
MDL No: | |
Molecular Formula: | C39H60O12 |
Molecular Weight: | 720.8865 |
Bafilomycin C1, a potent macrolide antibiotic derived from Streptomyces griseus, is widely utilized in chemical synthesis as a crucial tool for inhibiting vacuolar-type H+-ATPase (V-ATPase) activity. This inhibition of V-ATPase plays a pivotal role in the acidicification of intracellular compartments, thus impeding various cellular processes such as endocytosis, protein trafficking, and autophagy. By specifically targeting V-ATPase, Bafilomycin C1 offers researchers a precise and effective means to manipulate cellular pH levels and investigate the intricate mechanisms governing these crucial biological pathways. In the realm of chemical synthesis, the unique inhibitory properties of Bafilomycin C1 present a valuable opportunity to explore its application in the development of novel drug delivery systems, targeted drug therapies, and the study of cellular responses to altered pH environments.